European dermatology forum guidelines on topical photodynamic therapy

European Journal of Dermatology

Volumn 25, Issue 4, 2015, Pages 296-311

  Morton, Colin ^a   Szeimies, Rolf Markus ^b   Sidoroff, Alexis ^c   Wennberg, Ann Marie ^d   Basset Seguin, Nicole ^e   Calzavara Pinton, Piergiacomo ^f   Gilaberte, Yolanda ^g   Hofbauer, Günther ^h   Hunger, Robert ⁱ   Karrer, Sigrid ^j   Lehmann, Percy ^k   Piaserico, Stefano ^l   Ulrich, Claas ^m   Braathen, Lasse ⁱ  

^a Stirling Royal Infirmary   (United Kingdom)

^b Knappschaftskrankenhaus Recklinghausen   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e SAINT LOUIS HOSPITAL   (France)

^f SPEDALI CIVILI   (Italy)

^g HOSPITAL SAN JORGE   (Spain)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^k HELIOS KLINIKUM WUPPERTAL   (Germany)

^l UNIVERSITY OF PADOVA   (Italy)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

5 aminolaevulinic acid; Dermatology; Guidelines; Methyl aminolaevulinate; Non melanoma skin cancer; Photodynamic therapy

Indexed keywords

PHOTOSENSITIZING AGENT;

ACNE; ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CONDYLOMA ACUMINATUM; CRYOTHERAPY; DOSIMETRY; FLUORESCENCE IMAGING; FRACTIONATION; IMMUNOSUPPRESSIVE TREATMENT; LICHEN SCLEROSUS ET ATROPHICUS; LIGHT; NECROBIOSIS LIPOIDICA; NON MELANOMA SKIN CANCER; PHOTODYNAMIC THERAPY; POROKERATOSIS; PRACTICE GUIDELINE; PSORIASIS; SEBACEOUS GLAND HYPERPLASIA; SKIN LEISHMANIASIS; TOPICAL PHOTODYNAMIC THERAPY; ACNE VULGARIS; CARCINOMA IN SITU; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMAN; KERATOSIS, ACTINIC; LYMPHOMA, T-CELL, CUTANEOUS; PHOTOCHEMOTHERAPY; PROCEDURES; REJUVENATION; SKIN NEOPLASMS; STANDARDS;

ACNE VULGARIS; CARCINOMA IN SITU; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; KERATOSIS, ACTINIC; LIGHT; LYMPHOMA, T-CELL, CUTANEOUS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; REJUVENATION; SKIN NEOPLASMS;

EID: 84941792233     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2015.2570     Document Type: Article

References (243)

1. Braathen Lasse R, Szeimies Rolf M, Basset Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. J Am Acad Dermatol 2007; 56: 125-43.
2. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy. Br J Dermatol 2008; 159: 1245-66.
3. Morton CA, Szeimies R-M, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications-actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536-44.
4. Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 2: emerging indications-field cancerization, photorejuvenation and inflammatory/infective dermatoses. J Eur Acad Dermatol Venereol 2013; 27: 672-9.
5. http://www.euroderm.org/images/stories/guidelines/guideline_Management_Actinic_Keratoses-update2011.pdf.
6. http://www.euroderm.org/images/stories/guidelines/guideline_Basal_Cell_Carcinoma-update2012%20.pdf.
7. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6: 143-8.
8. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55: 145-57.
9. Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 2007; 157: 87-91.
10. Kuijpers D, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 2006; 5: 642-5.
11. Wiegell S, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol 2006; 54: 647-51.
12. Dirschka T, Radny P, Dominicus R, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratoses: results of a multicentre, randomized, observer-blind phase III study in comparison with registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166: 137-46.
13. Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009; 160: 1066-74.
14. Gerritsen MJP, Smits T, Kleinpenning MM, et al. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009; 218: 193-202.
15. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140: 17-23.
16. Nester MS, Gold MH, Kauvar ANB, et al. The use of photodynamic therapy in Dermatology: results of a consensus conference. J Drugs Dermatol 2006; 5: 140-54.
17. Braathen LR, Paredes BE, Saksela O, et al. Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol 2009; 23: 550-5.
18. Jang MS, Doh KS, Kang JS, et al. A comparative split-face study of photodynamic therapy with indocyanine green and indole-3-acetic acid for the treatment of acne vulgaris. Br J Dermatol 2011; 165: 1095-100.
19. Kacerovska D, Pizinger K, Majer F, et al. Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract-a pilot study. Photochem Photobiol 2008; 84: 779-85.
20. Rook AH, Wood GS, Duvic M, et al. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol 2010; 63: 984-90.
21. Baron ED, Malbasa CL, Santo-Domingo D, et al. Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers Surg Med 2010; 42: 728-35.
22. Morley S, Griffiths J, Philips G, et al. Phase IIa randomized, placebo-controlled study of antimicrobial photodynamic therapy in bacterially colonized, chronic leg ulcers and diabetic foot ulcers: a new approach to antimicrobial therapy. Br J Dermatol 2013; 168: 617-24.
23. Maisch T, Moor AC, Regensburger J, et al. Intense pulse light and 5-ALA PDT: phototoxic effects in vitro depend on the spectral overlap with protoporphyrin IX but do not match cut-off filter notations. Lasers Surg Med 2011; 43: 176-82.
24. Szeimies RM, Radny P, Sebastian M, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163: 386-94.
25. Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol 2010; 63: 195-211.
26. de Vijlder HC, Sterenborg HJ, Neumann HA, Robinson DJ, de Haas ER. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta DermVenereol 2012; 92: 641-7.
27. de Haas ER, Sterenborg HJ, Neumann HA, Robinson DJ. Response of Bowen disease to ALA-PDT using a single and a 2-fold illumination scheme. Arch Dermatol 2007; 143: 264-5.
28. de Haas ER, de Vijlder HC, Sterenborg HJ, et al. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2008; 22: 426-30.
29. Sotiriou E, Apalla Z, Chovarda E, et al. Single vs. fractionated photodynamic therapy for face and scalp actinic keratoses: a randomized, intra-individual comparison trial with 12 month follow-up. J Eur Acad Dermatol Venereol 2012; 26: 36-40.
30. Mosterd K, Thissen MRTM, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008; 159: 864-70.
31. de Bruijn HS, Meijers C, van der Ploeg-van den Heuvel A, et al. Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevulinate. J Photochem Photobiol B 2008; 92: 91-7.
32. Wiegell SR, Haedersdal M, Philipsen PA, et al. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blind study. Br J Dermatol 2008; 158: 740-746.
33. Wiegell SR, Fabricius S, Stender IM, et al. A randomized, multicentre study of directed daylight exposure times of 1 1/2 vs. 2 1/2 h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol 2011; 164: 1083-90.
34. Wiegell SR, Fabricius S, Gniadecka M, et al. Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp-a randomized multicentre study. Br J Dermatol 2012; 166: 1327-32.
35. Wiegell SR, Skødt V, Wulf HC. Daylight-mediated photodynamic therapy of basal cell carcinomas-an explorative study. J Eur Acad Dermatol Venereol 2013 Jan 7. doi: 10.1111/jdv.12076.
36. Moseley H, Allen JW, Ibbotson S, et al. Ambulatory photodynamic therapy: a new concept in delivering photodynamic therapy. Br J Dermatol 2006; 154: 747-50.
37. Attili SK, Lesar A, McNeill A, et al. An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. Br J Dermatol 2009; 161: 170-3.
38. Ibbotson SH, Ferguson J. Ambulatory photodynamic therapy using low irradiance inorganic light-emitting diodes for the treatment of nonmelanoma skin cancer: an open study. Photodermatol Photoimmunol Photomed 2012; 28: 235-9.
39. Moseley H. Total effective fluence: a useful concept in photodynamic therapy. Lasers Med Sci 1996; 11: 139-43.
40. Szeimies RM, Stockfleth E, Popp G, et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 2010; 162: 410-4.
41. Moseley H, Brancaleon L, Lesar AE, Ferguson J, Ibbotson SH. Does surface preparation alter ALA uptake in superficial non-melanoma skin cancer in vivo? Photodermatol Photoimmunol Photomed 2008; 24: 72-5.
42. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000; 142: 338-9.
43. Clementoni MT, Roscher M, Munavalli GS. Photodynamic photorejuvenation of the face with a combination of microneedling, red light, and broadband pulsed light. Lasers Surg Med 2010; 42: 150-9.
44. Kolde G, Rowe E, Meffert H. Effective photodynamic therapy of actinic keratosis and Bowen’s disease using microneedle perforation. Br J Dermatol 2013; 168: 450-1.
45. Whitaker IS, Shokrollahi K, James W, et al. Combined CO2 Laser With Photodynamic Therapy for the Treatment of Nodular Basal Cell Carcinomas. Ann Plast Surg 2007; 59: 484-8.
46. Togsverd-Bo K, Haak CS, Thaysen-Petersen D, Wulf HC, Anderson RR, Hædersdal M. Intensified Photodynamic Therapy of Actinic Keratoses with Fractional CO2 laser-a randomized. Br J Dermatol 2012; 166: 1262-9.
47. Wiegell SR, Wulf HC, Szeimies RM, et al. Daylight photodynamic therapy for actinic keratosis: an international consensus. J Eur Acad Dermatol Venereol 2012; 26: 673-9.
48. Cochrane C, Mordon SR, Lesage JC, Koncar V. New design of textile light diffusers for photodynamic therapy. Mater Sci Eng C Mater Biol Appl 2013; 33: 1170-5.
49. Fritsch CJ, Ruzicka T. Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. J Environ Pathol Toxicol Oncol 2006; 25: 425-39.
50. Lee CY, Kim KH, Kim YH. The efficacy of photodynamic therapy in delineating the lateral border between a tumour and a tumour-free area during Mohs micrographic surgery. Dermatol Surg 2010; 36: 1704-10.
51. Neus S, Ambichler T, Falk BG, Wohl S, Lehmann P. Preoperative assessment of basal cell carcinoma using conventional fluorescence diagnosis. Arch Derm Res 2009; 301: 289-94.
52. Tyrrell JS, Campbell SM, Curnow A SM. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Lasers Surg Med 2010; 42: 613-9.
53. Smits T, Kleinpenning M, Blokx M, van de Kerkhof PCM, van Erp PEJ, Gerritsen MJP. Fluorescence diagnosis in keratinocytic intraepidermal neoplasias. J Am Acad Dermatol 2007; 57: 824-31.
54. Wiegell SR, Skiveren PA, Philipsen PA, Wulf HC. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol 2008; 158: 727-33.
55. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded phase 3 multicenter trials. Arch Dermatol 2004; 140: 41-6.
56. Tarstedt M, Rosdahl I, Berne B, et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix®)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005; 85: 424-8.
57. Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155: 1029-36.
58. Tschen EH, Wong DS, Pariser DM, et al. The Phase IV ALA-PDT Actinic Keratosis Study Group. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol 2006; 155: 1262-9.
59. Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methylaminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 2013; 168: 825-36.
60. Wiegell SR, Fabricius S, Heydenreich J, et al. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations. Br J Dermatol 2013; 168: 186-91.
61. Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinatephotodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158: 994-9.
62. Sotiriou E, Apalla Z, Maliamani F, et al. Intra-individual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol 2009; 23: 1061-5.
63. Sotiriou E, Apalla Z, Chovarda E, Panagiotidou D, Ioannides D. Photodynamic therapy with 5-aminolevulinic acid in actinic keratosis: an 18-month clinical and histological follow-up. J Eur Acad Dermatol Venereol 2010; 24: 916-20.
64. Berking C, Herzinger T, Flaig MJ, et al. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg 2007; 33: 825-30.
65. Calzavara-Pinton PG, Rossi MT, Sala R, et al. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 2: Oncologic and infectious indication. s. J Photochem Photobiol Sci 2013; 12: 158-65.
66. Sotiriou E, Lallas A, Gooussi C, et al. Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis; a 12 month follow-up study. Br J Dermatol 2011; 165: 888-92.
67. Stockfleth E, et al. Guidelines on actinic keratosis. European Dermatology Forum. http://www.euroderm.org/edf/images/stories/guidelines/guideline_Management_Actinic_Keratosesupdate2011.pdf.
68. De Berker D, McGregor J, Hughes B. Guidelines for the management of actinic keratosis. Br J Dermatol 2007; 156: 222-30.
69. Serra-Guillen C, Nagore E, Hueso L, et al. A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate. Br J Dermatol 2011; 164: 429-33.
70. Morton CA, Horn M, Leman J, et al. A randomized, placebocontrolled, European study comparing MAL-PDT with cryotherapy and 5-fluorouracil in subjects with Bowen’s disease. Arch Dermatol 2006; 142: 729-35.
71. Lehmann P. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol 2007; 156: 793-801.
72. Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen’s disease and squamous cell carcinoma. Br J Dermatol 2008; 159: 137-44.
73. Truchuelo M, Fernandez-Guarino M, Fleta B, et al. Effectiveness of photodynamic therapy in Bowen’s disease: an observational and descriptive study in 51 lesions. J Eur Acad Dermatol Venereol 2012; 26: 868-74.
74. Cavicchini S, Serini SM, Fiorani R, et al. Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen’s disease. Int J Dermatol 2011; 50: 1002-5.
75. Lopez N, Meyer-Gonzalez T, Herrera-Acosta E, et al. Photodynamic therapy in the treatment of extensive Bowen’s disease. J Dermatolog Treat 2012; 23: 428-30.
76. Morton CA, Whitehurst C, McColl JH, et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137: 319-24.
77. Souza CS, Felicio LB, Ferreira J, et al. Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for non-melanoma skin cancer. Photodiagn Photodyn Ther 2009; 6: 207-13.
78. Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br J Dermatol 2003; 148: 539-43.
79. Morton CA, Whitehurst C, Moseley H, et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen’s disease. Br J Dermatol 1996; 135: 766-71.
80. Tyrrell JS, Morton C, Campbell SM, et al. Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. Br J Dermatol 2011; 164: 1362-8.
81. Wong TW, Sheu HM, Lee JY, et al. Photodynamic therapy for Bowen’s disease (squamous cell carcinoma in situ) of the digit. Dermatol Surg 2001; 27: 452-6.
82. Brookes PT, Jhawar S, Hinton CP, et al. Bowen’s disease of the nipple-a new method of treatment. Breast 2005; 14: 65-7.
83. Tan B, Sinclair R, Foley P. Photodynamic therapy for subungual Bowen’s disease. Australas J Dermatol 2004; 45: 172-4.
84. Usmani N, Stables GI, Telfer NR, et al. Subungual Bowen’s disease treated by topical ainolevulinic acid-photodynamic therapy. J Am Acad Dermatol 2005; 53: S273-6.
85. Souza CS, Felicio LB, Bentley MV, et al. Topical photodynamic therapy for Bowen’s disease of the digit in epidermolysis bullosa. Br J Dermatol 2005; 153: 672-4.
86. Guillen C, Sanmartin O, Escudero A, et al. Photodynamic therapy for in situ squamous cell carcinoma on chronic radiation dermatitis after photosensitization with 5-aminolaevulinic acid. J Eur Acad Dermatol Venereol 2000; 14: 298-300.
87. Ball SB, Dawber RP. Treatment of cutaneous Bowen’s disease with particular emphasis on the problem of lower leg lesions. Australas J Dermatol 1998; 39: 63-8.
88. Paoli J, Ternesten Bratel A, Lowhagen GB, et al. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm Venereol 2006; 86: 418-21.
89. Downs AM, Bower CB, Oliver DA, et al. Methyl aminolaevulinatephotodynamic therapy for actinic keratoses, squamous cell carcinoma in situ and superficial basal cell carcinoma employing a square wave intense pulsed light device for photoactivation. Br J Dermatol 2009; 161: 189-90.
90. Schreml S, Gantner S, Steinbauer J, et al. Melanoma promotion after photodynamic therapy of a suspected Bowen’s disease lesion. Dermatology 2009; 219: 279-81.
91. Cox N, Eedy D, Morton C. Guidelines for management of Bowen’s disease: 2006 update. Br J Dermatol 2007; 156: 11-21.
92. Hu A, Moore C, Yu E, et al. Evaluation of patient-perceived satisfaction with photodynamic therapy for Bowen disease. J Otolaryngol Head Neck Surg 2010; 39: 688-96.
93. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-53.
94. Szeimies R, Ibbotson S, Murrell D, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22: 1302-11.
95. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five year follow up of a randomized prospective trial of topical methyl aminolevulinatephotodynamic therapy versus surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143: 1131-6.
96. Foley P, Freeman M, Menter A, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 2009; 48: 1236-45.
97. Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25: 896-901.
98. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14: 647-54.
99. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-308.
100. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-40.
101. Roozeboom MH, Aardoom MA, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy after partial debulking vs. surgical excision in the treatment of nodular basal cell carcinoma: A randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 2013; 69: 280-7.
102. Berroeta L, Clark C, Dawe RS, et al. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low risk nodular BCC. Br J Dermatol 2007; 157: 401-3.
103. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for basal cell carcinoma-Effect of tumour thickness and duration of photosensitiser application on response. Arch Dermatol 1998; 134: 248-9.
104. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for’difficult-to-treat’ basal cell carcinoma. Br J Dermatol 2005; 152: 765-72.
105. Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrøm S. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol 2009; 23: 58-66.
106. Loncaster J, Swindell R, Slevin F, et al. Efficacy of photodynamic therapy as a treatment for Gorlin Syndrome-related basal cell carcinomas. Clin Oncol 2009; 21: 502-8.
107. Pauwels C, Mazereeuw-Hautier J, Basset-Seguin N, et al. Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient’s satisfaction and reduces the need for surgical procedures. J Eur Acad Dermatol Venereol 2011; 25: 861-4.
108. Telfer N, Colver G, Morton C. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
109. Hofbauer G, Bouwes Bavinck JN, Euvrard S. Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol 2010; 19: 473-82.
110. Hofbauer G, Anliker M, Arnold A, et al. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. SGDV working group for organ transplant recipients. Swiss Med Wkly 2009; 139: 407-15.
111. Dragieva C, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients. Transplantation 2004; 77: 115-21.
112. Dragieva C, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196-200.
113. Piaserico S, Belloni Fortina A, Rigotti P, et al. Topical photodynamic therapy of actinic keratosis in renal transplant patients. Transplant Proc 2007; 39: 1847-50.
114. Perrett CM, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: A randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156: 320-8.
115. Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol 2011; 165: 953-65.
116. Thoms KM, Kuschal C, Oetjen E, et al. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression. Exp Dermatol 2011; 20: 232-6.
117. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-5.
118. O’Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-4.
119. Ulrich C, Jurgensen JS, Degen A, et al. Prevention of nonmelanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161(Suppl 3): 78-84.
120. Wulf HC, Pavel S, Stender I, Bakker-Wensveen C. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-8.
121. Wennberg AM, Stenquist B, Stockfleth E, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new lesions in transplant recipients: a randomized study. Transplantation 2008; 86: 423-9.
122. De Graaf Y, Kennedy C, Wolterbeek R, et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organtransplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-74.
123. Willey A, Mehta S, Lee PK. Reduction in incidence of squamous cell carcinoma in solid organ transplant recipients treated by cyclic photodynamic therapy. Dermatol Surg 2010; 36: 652-8.
124. Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Cancer 1953; 6: 963-8.
125. Vauthey JN, Walsh GL, Vlastos G, Lauwers GY. Importance of field cancerisation in clinical oncology. Lancet Oncol 2000; 1: 15-6.
126. Basset-Seguin N, Moles JP, Mils V, Dereure O, Guilhou JJ. TP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol 1994; 103: 102S-106.
127. Ren ZP, Ponten F, Nister M, Ponten J. Two distinct p53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int J Cancer 1996; 69: 174-9.
128. Berg RJ, van Kranen HJ, Rebel HG, et al. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci U S A 1996; 93: 274-8.
129. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-30.
130. Ulrich M, Krueger-Corcoran D, Roewert-Huber J, et al. Confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology 2010; 220: 15-24.
131. Szeimies RM, Torezan L, Niwa A, et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150-9.
132. de Graaf YG, Rebel H, Elghalbzouri A, et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol 2008; 17: 349-55.
133. Basset-Seguin N, Baumann Conzett K, Gerritsen MJP, et al. Photodynamic therapy for actinic keratoses in organ transplant recipients. J Eur Acad Dermatol Venereol 2013; 27: 57-66.
134. Apalla Z, Sotiriou E, Chovarda E, et al. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 2010; 162: 171-5.
135. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-51.
136. Edstrom DW, Porwit A, Ros AM. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol 2001; 81: 184-8.
137. Orenstein A, Haik J, Tamir J, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg 2000; 26: 765-9.
138. Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994; 31: 678-80.
139. Ammann R, Hunziker T. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1995; 33: 541.
140. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol 2002; 27: 516-8.
141. Markham T, Sheahan K, Collins P. Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol 2001; 144: 1262-3.
142. Zane C, Venturini M, Sala R, Calzavara R, Pinton P. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2006; 22: 254-8.
143. Fernandez-Guarino M, Harto A, Perez-Garcia B, Montull C, De Las Heras E, Jaen P. Plaque-phase mycosis fungoides treated with photodynamic therapy: results in 12 patients. Actas Dermosifilogr 2010; 101: 785-91.
144. Kim ST, Kang DY, Kang JS, Baek JW, Jeon YS, Suh KS. Photodynamic therapy with methyl-aminolaevulinic acid for mycosis fungoides. Acta Derm Venereol 2012; 92: 264-8.
145. Quereux G, Brocard A, Saint-Jean M, et al. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature. J Am Acad Dermatol 2013; 69: 890-7.
146. Kjeldstad B, Johnsson A. An action spectrum for blue and near ultraviolet inactivation of propionibacterium acnes; with emphasis on a possible porphyrin photosensitization. Photochem Photobiol 1986; 43: 67-70.
147. Divaris DX, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol 1990; 136: 891-7.
148. Sakamoto FH, Lopes JD, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice Part 1 Acne: when and why consider photodynamic therapy? J Am Acad Dermatol 2010; 63: 183-93.
149. Hongcharu W, Taylor CR, Chang Y, et al. Topical ALAphotodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000; 115: 183-92.
150. Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. J Dermatol 2001; 144: 575-9.
151. Pollock B, Turner D, Stringer MR, et al. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol 2004; 151: 616-22.
152. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006; 154: 969-76.
153. Horfelt C, Funk J, Frohm-Nilsson M, Wiegleb Edstrom D, Wennberg AM. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006; 155: 608-13.
154. Horfelt C, Stenquist B, Larko O, Faergemann J, Wennberg AM. Photodynamic therapy for acne vulgaris: a pilot study of the dose-response and mechanism of action. Acta Derm Venereol 2007; 87: 325-9.
155. Elman M, Lebzelter J. Light therapy in the treatment of acne vulgaris. Dermatol Surg 2004; 30: 139-46.
156. Yang GL, Zhao M, Wang JM, et al. Short-term clinical effects of photodynamic therapy with topical 5-aminolevulinic acid for facial acne conglobate: an open, prospective, parallel-arm trial. Photodermatol Photoimmunol Photomed 2013; 29: 233-8.
157. Stender IM, Lock-Andersen J, Wulf HC. Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5-aminolaevulinic acid: a pilot study. Clin Exp Dermatol 1999; 24: 154-9.
158. Stender IM, Na R, Fogh H, et al. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000; 355: 963-6.
159. Fernandez-Guarino M, Harto A, Jaen P. Treatment of recalcitrant viral warts with pulsed dye laser MAL-PDT. J Dermatol Treat 2011; 22: 226-8.
160. Ohtsuki A, Hasegawa T, Hirasawa Y, et al. Photodynamic therapy using light-emitting diodes for the treatment of viral warts. J Dermatol 2009; 36: 525-8.
161. Schroeter CA, Kaas L, Waterval JJ, et al. Successful treatment of periungual warts using photodynamic therapy: a pilot study. J Eur Acad Dermatol Venereol 2007; 21: 1170-4.
162. Schroeter CA, Pleunis J, van Nispen tot Pannerden C, et al. Photodynamic therapy: new treatment for therapy-resistant plantar warts. Dermatol Surg 2005; 31: 71-5.
163. Smucler R, Jatsova E. Comparative study of aminolevulic acid photodynamic therapy plus pulsed dye laser versus pulsed dye laser alone in treatment of viral warts. Photomed Laser Surg 2005; 23: 202-5.
164. Chong WS, Kang GY. Dramatic clearance of a recalcitrant acral viral wart using methyl aminolevulinate-red light photodynamic therapy. Photodermatol Photoimmunol Photomed 2009; 25: 225-6.
165. Lu YG, Wu JJ, He Y, et al. Efficacy of topical aminolevulinic acid photodynamic therapy for the treatment of verruca planae. Photomed Laser Surg 2010; 28: 561-3.
166. Mizuki D, Kaneko T, Hanada K. Successful treatment of topical photodynamic therapy using 5-aminolevulinic acid for plane warts. Br J Dermatol 2003; 149: 1087-8.
167. Fehr MK, Hornung R, Degen A, et al. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med 2002; 30: 273-9.
168. Yang YG, Zou XB, Zhao H, et al. Photodynamic therapy of condyloma acuminata in pregnant women. Chinese Med J 2012; 125: 2925-8.
169. Stefanaki IM, Georgiou S, Themelis GC, et al. In vivo fluorescence kinetics and photodynamic therapy in condylomata acuminata. Br J Dermatol 2003; 149: 972-6.
170. Wang XL, Wang HW, Wang HS, et al. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. Br J Dermatol 2004; 151: 880-5.
171. Chen K, Chang BZ, Ju M, et al. Comparative study of photodynamic therapy vs CO2 laser vaporization in treatment of condylomata acuminata: a randomized clinical trial. Br J Dermatol 2007; 156: 516-20.
172. Liang J, Lu XN, Tang H, et al. Evaluation of photodynamic therapy using topical aminolevulinic acid hydrochloride in the treatment of condylomata acuminata: a comparative, randomized clinical trial. Photodermatol Photoimmunol Photomed 2009; 25: 293-7.
173. Szeimies RM, Schleyer V, Moll I, et al. Adjuvant photodynamic therapy does not prevent recurrence of condylomata acuminata after carbon dioxide laser ablation-A phase III, prospective, randomized, bicentric, double-blind study. Dermatol Surg 2009; 35: 757-64.
174. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006; 31: 634-7.
175. Pizinger K, Cetkovska P, Kacerovska D, Kumpova M. Successful treatment of cutaneous leishmaniasis by photodynamic therapy and cryotherapy. Eur J Dermatol 2009; 19: 172-3.
176. Enk CD, Fritsch C, Jonas F, et al. Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol 2003; 139: 432-4.
177. Ghaffarifar F, Jorjani O, Mirshams M, Miranbaygi MH, Hosseini ZK. Photodynamic therapy as a new treatment of cutaneous leishmaniasis. East Mediterr Health J 2006; 12: 902-8.
178. Sohl S, Kauer F, Paasch U, Simon JC. Photodynamic treatment of cutaneous leishmaniasis. J Dtsch Dermatol Ges 2007; 5: 128-30.
179. Gardlo K, Hanneken S, Ruzicka T, Neumann NJ. Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality. Hautarzt 2004; 55: 381-3.
180. van der Snoek EM, Robinson DJ, van Hellemond JJ, Neumann HA. A review of photodynamic therapy in cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2008; 22: 918-22.
181. Enk CD. Treatment of cutaneous leishmaniasis with daylight activated PDT. In: t. A. C. o. t. E. S. f. P. Therapy editor. Madrid 2013.
182. Evangelou G, Krasagakis K, Giannikaki E, Kruger-Krasagakis S, Tosca A. Successful treatment of cutaneous leishmaniasis with intralesional aminolevulinic acid photodynamic therapy. Photodermatol Photoimmunol Photomed 2011; 27: 254-6.
183. Akilov OE, Kosaka S, O’Riordan K, Hasan T. Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. Exp Dermatol 2007; 16: 651-60.
184. Reveiz L, Maia-Elkhoury AN, Nicholls RS, Romero GA, Yadon ZE. Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. PLoS One 2013; 8: e61843.
185. Karrer S, Kohl E, Feise K, et al. Photodynamic therapy for skin rejuvenation: review and summary of the literature-results of a consensus conference of an expert group for aesthetic photodynamic therapy. J Dtsch Dermatol Ges 2013; 11: 137-48.
186. Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic photorejuvenation. Dermatol Surg 2002; 28: 742-4.
187. Avram DK, Goldman MP. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol 2004; 3(1 Suppl): S36-9.
188. Alster TS, Tanzi EL, Welsh EC. Photorejuvenation of facial skin with topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a split-face comparison study. J Drugs Dermatol 2005; 4: 35-8.
189. Dover JS, Bhatia AC, Stewart B, Arndt KA. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol 2005; 141: 1247-52.
190. Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA. Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. Dermatol Surg 2006; 32: 795-801; discussion 801-3.
191. Bjerring P, Christiansen K, Troilius A, Bekhor P, de Leeuw J. Skin fluorescence controlled photodynamic photorejuvenation (wrinkle reduction). Lasers Surg Med 2009; 41: 327-36.
192. Kosaka S, Yasumoto M, Akilov OE, Hasan T, Kawana S. Comparative split-face study of 5-aminolevulinic acid photodynamic therapy with intense pulsed light for photorejuvenation of Asian skin. J Dermatol 2010; 37: 1005-10.
193. Haddad A, Santos ID, Gragnani A, Ferreira LM. The effects of increasing fluence on the treatment of actinic keratosis and photodamage by photodynamic therapy with 5-aminolevulinic acid and intense pulsed light. Photomed Las Surg 2011; 29: 427-32.
194. Piccioni A, Fargnoli MC, Schoinas S, et al. Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skin. J Dermatol Treat 2011; 22: 247-53.
195. Xi Z, Shuxian Y, Zhong L, et al. Topical 5-aminolevulinic acid with intense pulsed light versus intense pulsed light for photodamage in Chinese patients. Dermatol Surg 2011; 37: 31-40.
196. Babilas P, Knobler R, Hummel S, et al. Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Br J Dermatol 2007; 157: 111-7.
197. Zane C, Capezzera R, Sala R, Venturini M, Calzavara-Pinton P. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med 2007; 39: 203-9.
198. Ruiz-Rodriguez R, Lopez L, Candelas D, Pedraz J. Photorejuvenation using topical 5-methyl aminolevulinate and red light. J Drugs Dermatol 2008; 7: 633-7.
199. Issa MC, Pineiro-Maceira J, Vieira MT, et al. Photorejuvenation with topical methyl aminolevulinate and red light: a randomized, prospective, clinical, histopathologic, and morphometric study. Dermatol Surg 2010; 36: 39-48.
200. Sanclemente G, Medina L, Villa JF, Barrera LM, Garcia HI. A prospective split-face double-blind randomized placebo-controlled trial to assess the efficacy of methyl aminolevulinate + red-light in patients with facial photodamage. J Eur Acad Dermatol Venereol 2011; 25: 49-58.
201. Gold MH. The evolving role of aminolevulinic hydrochloride with photodynamic therapy in photoaging. Cutis 2002; 69: 41-6.
202. Goldman MP, Atkin D, Kincad S. PDT/ALA in the treatment of actinic damage: real world experience. Lasers Med Surg 2002; 14(S): 24.
203. Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004; 140: 33-40.
204. Torezan L, Chaves Y, Niwa A, Sanches JA, Festa-Neto C, Szeimies RM. A pilot split-face study comparing methyl aminolevulinate-photodynamic therapy (PDT) with microneedlingassisted PDT on actinically damaged skin. Dermatol Surg 2013; 39: 1197-201.
205. Ruiz-Rodriguez R, Lopez L, Candelas D, Zelickson B. Enhanced efficacy of photodynamic therapy after fractional resurfacing: fractional photodynamic rejuvenation. J Drugs Dermatol 2007; 6: 818-20.
206. Marmur ES, Phelps R, Goldberg DJ. Ultrastructural changes seen after ALA-IPL photorejuvenation: a pilot study. J Cosmet Laser Ther 2005; 7: 21-4.
207. Orringer JS, Voorhees JJ, Hamilton T, et al. Dermal matrix remodeling after nonablative laser therapy. J Am Acad Dermatol 2005; 53: 775-82.
208. Park MY, Sohn S, Lee ES, Kim YC. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis. J Am Acad Dermatol 2010; 62: 85-95.
209. Park JY, Jang YH, Kim YS, Sohn S, Kim YC. Ultrastructural changes in photorejuvenation induced by photodynamic therapy in a photoaged mouse model. Eur J Dermatol 2013; 23: 471-7.
210. Jang YH, Koo GB, Kim JY, Kim YS, Kim YC. Prolonged activation of ERK contributes to the photorejuvenation effect in photodynamic therapy in human dermal fibroblasts. J Invest Dermatol 2013; 133: 2265-75.
211. Bagazgoitia L, Cuevas Santos J, Juarranz A, Jaen P. Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 2011; 165: 144-51.
212. Calzavara-Pinton PG, Rossi MT, Aronson E, Sala R. Italian Group For Photodynamic Therapy. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications. Photochem Photobiol Sci 2013; 12: 148-57.
213. Schleyer V, Radakovic-Fijan S, Karrer S, et al. Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. J Eur Acad Dermatol Venereol 2006; 20: 823-8.
214. Alster TS, Tanzi EL. Photodynamic therapy with topical aminolevulinic acid and pulsed dye laser irradiation for sebaceous hyperplasia. J Drugs Dermatol 2003; 2: 501-4.
215. Sakamoto F, Izikson L, Tannous Z, Zurakowski D, Anderson RR. Surgical scar remodelling after photodynamic therapy using aminolaevulinic acid or its methylester: a retrospective, blinded study of patients with field cancerization. Br J Dermatol 2012; 166: 413-6.
216. Campbell SM, Tyrrell J, Marshall R, Curnow A. Effect of MALphotodynamic therapy on hypertrophic scarring. Photodiagn Photodyn Ther 2010; 7: 183-8.
217. Ud-Din S, Thomas G, Morris J, et al. Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools. Arch Dermatol Res 2013; 305: 205-14.
218. Hillemanns P, Untch M, Pro□ve F, Baumgartner R, Hillemanns M, Korell M. Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid. Obstet Gynecol 1999; 93: 71-4.
219. Romero A, Hernandez-Nuñez A, Cordoba-Guijarro S, Arias-Palomo D, Borbujo-Martiĭnez J. Treatment of recalcitrant erosive vulvar lichen sclerosus with photodynamic therapy. J Am Acad Dermatol 2007; 57(2 Suppl): S46-7.
220. Sotiriou E, Apalla Z, Patsatsi A, Panagiotidou D. Recalcitrant vulvar lichen sclerosis treated with aminolevulinic acid-photodynamic therapy: a report of five cases. J Eur Acad Dermatol Venereol 2008; 22: 1398-9.
221. Weisenseel P, Kuznetsov AV, Molin S, Ruzicka T, Berking C, Prinz JC. Photodynamic therapy for granuloma annulare: more than a shot in the dark. Dermatology 2008; 217: 329-32.
222. Berking C, Hegyi J, Arenberger P, Ruzicka T, Jemec GB. Photodynamic therapy of necrobiosis lipoidica-a multicenter study of 18 patients. Dermatology 2009; 218: 136-9.
223. Nayeemuddin FA, Wong M, Yell J, Rhodes LE. Topical photodynamic therapy in disseminated superficial actinic porokeratosis. Clin Exp Dermatol 2002; 27: 703-6.
224. Curkova AK, Hegyi J, Kozub P, Szep Z, D’Erme AM, Simaljakova M. A case of linear porokeratosis treated with photodynamic therapy with confocal microscopy surveillance. Dermatol Ther 2014; 27: 144-7.
225. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinatebased photodynamic therapy alone and with prior curettage. Br J Dermatol 2001; 145: 467-71.
226. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate (Metvix®) is effective and safe in the treatment of actinic keratoses: results of a prospective randomized trial. J Am Acad Dermatol 2003; 48: 227-32.
227. Lehmann P. Nebenwirkungen der topischen photodynamischen Therapie. Hautarzt 2007; 58: 597-603.
228. Gholam P, Kroehl V, Enk AH. Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis. Dermatology 2013; 226: 253-9.
229. Schmutz JL, Barbaud A, Trechot P. Erosive pustulosis on the scalp following dynamic phototherapy. Ann Dermatol Venereol 2010; 137: 86.
230. Harries MJ, Street G, Gilmour E, Rhodes LE, Beck MH. Allergic contact dermatitis to methyl aminolevulinate (Metvix) cream used in photodynamic therapy. Photodermatol Photoimmunol Photomed 2007; 23: 35-6.
231. Korshoj S, Solvsten H, Erlandsen M, Sommerlund M. Frequency of sensitization to methyl aminolaevulinate after photodynamic therapy. Contact Dermatitis 2009; 60: 320-4.
232. Wolfe CM, Green WH, Hatfield HK, Cognetta AB Jr. Urticaria after methyl aminolevulinate photodynamic therapy in a patient with nevoid basal cell carcinoma syndrome. J Drugs Dermatol 2012; 11: 1364-5.
233. Borroni RG, Cargno A, Rivetti N, Arbustini E, Brazzelli V. Risk of acute postoperative hypertension after topical photodynamic therapy for non-melanoma skin cancer. Photodermatol Photoimmunol Photomed 2013; 29: 73-7.
234. Rakvit P, Kerr AC, Ibbotson SH. Localized bullous pemphigoid induced by photodynamic therapy. Photodermatol Photoimmunol Photomed 2011; 27: 251-3.
235. Mikolajewska P, Rømoen OT, Martinsen OG, et al. Bioimpedance for pain monitoring during cutaneous photodynamic therapy: Preliminary study. Photodiagnosis Photodyn Ther 2011; 8: 307-13.
236. Zeitouni NC, Paquette AD, Housel JP, et al. A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. Lasers Surg Med 2013; 45: 89-94.
237. Grapengiesser S, Ericson M, Gudmundsson F, Larko O, Rosen A, Wennberg AM. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27: 493-7.
238. Sandberg C, Stenquist B, Rosdahl I, et al. Important factors for pain during photodynamic therapy for actinic keratosis. Acta Derm Venereol 2006; 86: 404-8.
239. Halldin CB, Gillstedt M, Paoli J, Wennberg AM, Gonzalez H. Predictors of pain associated with photodynamic therapy: a retrospective study of 658 treatments. Acta Derm Venereol 2011; 91: 545-51.
240. Ericson MB, Sandberg C, Stenquist B, et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 2004; 151: 1204-12.
241. Paoli J, Halldin C, Ericson MB, Wennberg AM. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol. 2008; 33: 559-64.
242. Halldin CB, Paoli J, Sandberg C, Gonzalez H, Wennberg AM. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Clin Exp Dermatol 2008; 33: 559-64.
243. Serra-Guillen C, Hueso L, Nagore E, et al. Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratosis of the frontotemporal zone. Br J Dermatol 2009; 161: 353-6.